Contents

Extension trial of ranibizumab for choroidal neovascularization secondary to age-related macular degeneration (HORIZON)

April 1, 2012

Clinical trial

Ranibizumab for macular edema due to retinal vein occlusions: long-term follow-up in the HORIZON trial.

Heier JS, Campochiaro PA, Yau L, Li Z, Saroj N, Rubio RG, Lai P.

Ophthalmology. 2012 Apr;119(4):802-9.
Full text | Metrics.

Main finding: There was a decline in vision in CRVO patients, but vision in BRVO patients remained stable. CRVO patients may require more frequent follow-up than every 3 months.

 

  • Purpose: To assess long-term safety and efficacy of intraocular ranibizumab injections in patients with macular edema after retinal vein occlusion
  • Study type: Open label extension trial
  • Condition: Central/Branch retinal vein occlusion

Participants: BRAVO/CRUISE participants

 

  • n=304 (from BRAVO), 304 (from CRUISE)

 

Intervention:

 

Patients were seen at least every 3 months and given intravitreal ranibizumab 0.5mg if they met retreatment criteria.

Vision in BRVO patients remained stable, while CRVO had a decline in vision. This could be due to reduced follow up and fewer ranibizumb injections in the second year of treatment.

 

 

BRVO CRVO
Mean no. of injections 2-2.4 2.9-3.8
Change in BCVA score (letter) -2.3 to +0.9 -5.2 to -4.1

Share This Article :

Updated on March 7th, 2022

Source Archive

© 2025 - sourceshed